Clinical trial
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
NCT03519256 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 2, 2018
- Completion date
- August 24, 2022
- Enrollment
- 142 (actual)
- Sites
- 88
Conditions
As the registry lists them; a condition with its own page is linked.